Akebia Therapeutics Revenue, Profits - AKBA Quarterly Income Statement

Add to My Stocks
$8.33 $0.59 (7.62%) AKBA stock closing price Sep 20, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Akebia Therapeutics stock price. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. The income statement for AKBA which shows a YOY revenue growth of 6.23% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The Akebia Therapeutics profit and loss statement for 2018 Q2 shows a net profit of $-34.07M. Profits for last year was $-23.42M. Apart from this an investor should also check Akebia Therapeutics assets and Akebia Therapeutics free cash flow.

View and download details of revenue and profits for Akebia Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Akebia Therapeutics Revenues or Net Sales
48.79M45.93M87.32M41.28M28.52M20.87M1.54M---
Cost Of Goods Sold (COGS)----------
Akebia Therapeutics Gross Profit
48.79M45.93M87.32M41.28M28.52M20.86M1.53M---
Research & Development Expense71.92M61.4M68.39M58.71M43.75M60.04M33.45M31.23M30.87M20.23M
Selling General & Admin Expense12.54M9.02M7.58M6.74M6.9M5.78M6.15M4.94M5.31M5.81M
Income Before Depreciation Depletion Amortization-35.66M-24.49M11.36M-24.17M-22.13M-44.97M-38.06M-36.18M-36.18M-26.04M
Depreciation Depletion Amortization----------
Non Operating Income1.59M1.08M-1.04M----0.12M--
Interest Expense----------
Akebia Therapeutics Pretax Income
-34.07M-23.41M12.27M-23.13M-21.51M-44.54M-37.88M-36.3M-35.77M-25.79M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-34.07M-23.42M12.28M-23.13M-21.52M-44.54M-37.86M-36.31M-35.78M-25.8M
Extraordinary Items & Discontinued Operations----------
Akebia Therapeutics Profit/ Loss (Net Income)
-34.07M-23.42M12.28M-23.13M-21.52M-44.54M-37.86M-36.31M-35.78M-25.8M
Average Shares used to compute Diluted EPS56.89M48.61M49.72M46.94M40.82M38.76M38.28M37.9M37.81M36.87M
Average Shares used to compute Basic EPS56.89M48.61M47.35M46.94M40.82M38.76M38.28M37.9M37.81M36.87M
Income Before Nonrecurring Items-34.07M-23.42M12.28M-23.13M-21.52M-44.54M-37.86M-36.31M-35.78M-25.8M
Income from Nonrecurring Items----------
Akebia Therapeutics Earnings Per Share Basic Net
-0.60-0.480.26-0.49-0.53-1.15-0.99-0.96-0.95-0.70
Akebia Therapeutics Earnings Per Share Diluted Net
-0.60-0.480.25-0.49-0.53-1.15-0.99-0.96-0.95-0.70
EPS Diluted Before Nonrecurring Items-0.60-0.480.25-0.49-0.53-1.15-0.99-0.96-0.95-0.70
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Before investing one should read a report on Akebia Therapeutics stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A QoQ growth - See: Akebia Therapeutics revenue chart, implies that the company is growing. It has been the case with Akebia Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. AKBA stock had a poor bottom line growth.

The income statement is also called statement of revenue and expense. The AKBA financials along with Akebia Therapeutics historical stock prices provide a lot of details about the firm.

Akebia Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
2.12
Dividend Yield
0%